Integra LifeSciences (NASDAQ:IART) Reaches New 52-Week High – Should You Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $18.92 and last traded at $18.7530, with a volume of 147081 shares changing hands. The stock had previously closed at $18.76.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Truist Financial dropped their price target on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. Wall Street Zen raised Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and increased their price target for the stock from $11.00 to $16.00 in a research note on Thursday, May 28th. Wells Fargo & Company boosted their target price on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. One research analyst has rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $16.20.

Integra LifeSciences Stock Up 0.4%

The stock has a market capitalization of $1.47 billion, a P/E ratio of -2.92, a P/E/G ratio of 1.30 and a beta of 1.24. The stock’s 50 day simple moving average is $14.84 and its 200 day simple moving average is $12.52. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. During the same period in the previous year, the company earned $0.41 earnings per share. Integra LifeSciences’s quarterly revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IART. Global Retirement Partners LLC bought a new position in shares of Integra LifeSciences in the fourth quarter valued at $25,000. Osaic Holdings Inc. lifted its stake in Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares in the last quarter. GAMMA Investing LLC boosted its stake in Integra LifeSciences by 145.9% in the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 3,742 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Integra LifeSciences by 595.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after buying an additional 6,814 shares during the period. Finally, Virtu Financial LLC purchased a new position in Integra LifeSciences during the 4th quarter valued at about $124,000. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.